The 2018 GU Cancers Symposium is the premier scientific and educational meeting .
| |
| [08-February-2018] |
| SAN DIEGO, Feb. 8, 2018 /PRNewswire/ -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced that its Decipher® Prostate Biopsy, Prostate RP and Bladder TURBT as well as analysis from the Decipher Genomics Resource Information Database (Decipher GRID®) registry will be featured in oral and poster presentations at the 2018 Genitourinary (GU) Cancers Symposium, held February 8-10, 2018, in San Francisco, California. The 2018 GU Cancers Symposium is the premier scientific and educational meeting designed to meet the needs of physicians and other members of the cancer care and research community who diagnose, treat and study malignancies in the genitourinary system, which includes the organs of the reproductive and urinary systems. “This year, the GU Cancers Symposium will include a record number of abstracts featuring Decipher tests and Decipher GRID registry studies, demonstrating the applicability of our platform across a broad population of prostate and bladder cancer patients,” said Doug Dolginow, MD, chief executive officer of GenomeDx. “We applaud the physicians and institutions conducting these studies, and are focused on working with the medical community to establish Decipher as a standard of care.” Oral Presentation Poster Presentations - Session A: Prostate Cancer and Trials in Progress - Thursday, February 8th - 11:30 a.m. to 1:00 p.m. and 5:15 p.m. to 6:15 p.m. (PT) Title: Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass Title: Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer Title: Genomic variations associated with prostate cancer in large cohort of African American men Title: Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification Title: A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer Title: Validation of a genomic classifier to predict adverse pathology in men diagnosed with low risk prostate cancer Title: Impact of genomic risk scores on treatment decisions following radical prostatectomy in a prospective Medicare registry Title: The diverse genomic landscape of low−risk prostate cancer Title: Impact of Decipher test on adjuvant and salvage treatments received following radical prostatectomy Title: Validation of a genomic risk classifier to predict metastasis and prostate cancer-specific mortality in men with positive lymph nodes Title: Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications Title: Prospective randomized trial of genomic classifier impact on treatment decisions in patients at high risk of recurrence following radical prostatectomy (G-MINOR) Poster Presentations - Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers and Trials in Progress - Friday, February 9th - 12:15 p.m. to 1:45 p.m. and 6:00 p.m. to 7:00 p.m. (PT) Title: Apparent plasticity in the biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer Title: A genomic classifier for identifying a neuroendocrine-like bladder cancer subtype Title: Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy About Decipher Cancer Classifier Tests and GRID GenomeDx’s Decipher prostate and bladder cancer classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher RP is indicated for men after prostate removal surgery, and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to help determine which patients may be more likely to benefit from additional treatment. The Decipher tests are derived from GenomeDx’s Decipher Genomics Resource Information Database (GRID). GRID contains the genomic profiles of tens of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world’s largest global RNA expression databases using cloud-based analytics. Each tumor analyzed with a Decipher test adds new data to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID make genetic information accessible for researchers to predict responses to therapy better and to guide treatment more precisely. In addition, GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment. Learn more at www.deciphertest.com and www.deciphergrid.com About GenomeDx Biosciences GenomeDx is reimagining the use of genomics as a platform for mass collaboration to improve patient treatment and outcomes through its currently available genomic tests for prostate and bladder cancer as well as potential future tests. GenomeDx is headquartered in Vancouver, British Columbia, and operates a clinical laboratory in San Diego, California. Learn more at http://www.genomedx.com/
View original content with multimedia:http://www.prnewswire.com/news-releases/genomedx-biosciences-decipher-tests-and-decipher-grid-to-be-featured-in-multiple-presentations-at-2018-genitourinary-cancers-symposium-300596029.html SOURCE GenomeDx Biosciences |
